Anesthesiology Research Analysis
In 2025, anesthesiology advanced through mechanistic discoveries and precision frameworks that reshape perioperative science. Structural pharmacology located a conformation-specific propofol pocket in HCN1, while epitope-resolved immunology mapped anti-rocuronium antibodies that can trigger anaphylaxis, enabling structure- and epitope-guided safety. Non-opioid trajectories matured, from an arrestin-biased NTSR1 analgesic with strong preclinical efficacy to a phase 1 orexin-2 agonist reversing op
Summary
In 2025, anesthesiology advanced through mechanistic discoveries and precision frameworks that reshape perioperative science. Structural pharmacology located a conformation-specific propofol pocket in HCN1, while epitope-resolved immunology mapped anti-rocuronium antibodies that can trigger anaphylaxis, enabling structure- and epitope-guided safety. Non-opioid trajectories matured, from an arrestin-biased NTSR1 analgesic with strong preclinical efficacy to a phase 1 orexin-2 agonist reversing opioid-induced respiratory depression without sacrificing analgesia. Precision physiologic methods accelerated: unsupervised endotyping reframed hypotension as mechanistic states, and a bedside ARDS classifier linked phenotype dynamics to heterogeneous steroid effects. Practice-changing RCTs reoriented blood management toward PCC-first factor replacement and mechanistic trials showed hyperoxia impairs vascular function via sGC redox. Translational biology connected innate immunity (suPAR) to renal vasoconstriction, and human cell-type genomics localized chronic pain risk to specific cortical and hDRG neurons. Collectively, these studies set a new foundation for mechanism-driven, phenotype-guided perioperative care.
Selected Articles
1. Arrestin-biased allosteric modulator of neurotensin receptor 1 alleviates acute and chronic pain.
A β-arrestin–biased NTSR1 positive allosteric modulator delivered broad analgesia across multiple pain paradigms with mechanistic specificity and fewer opioid-like liabilities, opening a non-opioid analgesic trajectory with strong translational promise.
Impact: Defines a mechanistically distinct, druggable analgesic pathway that could pivot perioperative and chronic pain management away from opioids.
Clinical Implications: Supports IND-enabling work toward early-phase human trials; if efficacy translates, perioperative protocols could reduce opioid reliance with improved safety profiles.
Key Findings
- Robust analgesia across postoperative, inflammatory, and neuropathic models
- β-arrestin-2–dependent mechanisms with NMDA/ERK suppression
- Reduced reward, constipation, and withdrawal-like behaviors vs opioids
Methodological Strengths
- Multi-model analgesia testing with convergent mechanistic assays
- Comprehensive behavioral safety profiling vs opioids
Limitations
- Preclinical only; human efficacy and safety unknown
- Dose–exposure relationships and PK/PD in humans untested
Future Directions: Advance IND-enabling toxicology, PK/PD, and first-in-human trials; develop biomarkers of NTSR1/β-arrestin engagement and explore combination strategies with non-opioid standards.
This preclinical study reports SBI-810, a β-arrestin–biased positive allosteric modulator of neurotensin receptor 1 (NTSR1), producing robust analgesia across postoperative, inflammatory, and neuropathic rodent pain models. Mechanistic investigations demonstrate dependence on NTSR1 and β-arrestin-2, suppression of NMDA/ERK signaling, and reduced Nav1.7 surface expression. Compared with opioids, SBI-810 showed lower reward, constipation, and withdrawal-like behaviors. Findings nominate a non-opioid, mechanistically distinct pathway for analgesia with translational potential.
2. The cell-type-specific genetic architecture of chronic pain in brain and dorsal root ganglia.
Human genetics intersected with single-cell atlases to pinpoint cortical and hDRG neuronal cell types driving chronic pain risk, establishing a roadmap for precision analgesic targets and stratification.
Impact: Translates GWAS signals into cell-type–level targets, accelerating mechanism-driven analgesic discovery and biomarker development.
Clinical Implications: Guides target selection for drug discovery and patient stratification toward glutamatergic cortical circuits and defined hDRG nociceptors.
Key Findings
- Pain heritability enriched in specific cortical glutamatergic neurons
- Robust enrichment in a defined human DRG nociceptor subtype
- Candidate pathways include kinase signaling and GABAergic synapses
Methodological Strengths
- Integration of GWAS with human single-cell multi-omics
- Cell-type–resolved enrichment with cross-tissue validation
Limitations
- Associational analyses require functional validation
- Clinical translation and target tractability not yet established
Future Directions: Functional validation of prioritized cell types and pathways; develop circuit-level biomarkers and stratified trial designs leveraging identified cell-type signatures.
Integrating large-scale pain GWAS with human single-cell transcriptomic and chromatin datasets, this study localizes heritability for chronic pain to discrete cortical glutamatergic neuron populations and a defined human DRG nociceptor subtype. Enrichment analyses highlight pathways including kinase signaling, GABAergic synapses, and axon guidance. The results provide a cell-type–resolved map from human genetics to neuronal circuits, nominating actionable targets for precision analgesia and informing biomarker development.
3. A propofol binding site in the voltage sensor domain mediates inhibition of HCN1 channel activity.
Multimodal structural and functional approaches pinpoint a conformation-specific propofol pocket in HCN1’s voltage sensor, establishing a blueprint for structure-guided anesthetic/channel modulation.
Impact: Reveals a druggable, state-specific anesthetic site, enabling selective HCN modulation and advancing mechanistic anesthetic pharmacology.
Clinical Implications: Informs development of next-generation modulators that preserve beneficial effects while minimizing bradycardia and off-target actions.
Key Findings
- Propofol pocket localized to HCN1 S3–S4 voltage sensor region
- Resting-state pocket supported by molecular dynamics
- Pocket-residue mutations abolish voltage-dependent inhibition
Methodological Strengths
- Triangulation across photoaffinity, MD simulations, and electrophysiology
- Structure–function mutagenesis validating causality
Limitations
- In vitro systems; in vivo confirmation of anesthetic-state occupancy is needed
- Clinical translation of selective HCN modulators remains to be established
Future Directions: Design state-selective HCN modulators; delineate systems-level contributions of HCN1 to anesthetic endpoints and cardiac effects.
Using photoaffinity labeling, mass spectrometry, molecular dynamics, and mutagenesis/electrophysiology, this study identifies a resting-state pocket in the HCN1 voltage-sensor domain where propofol binds to mediate voltage-dependent inhibition. Mutations in pocket residues abolish propofol’s inhibitory effect, implicating a conformation-specific mechanism. Findings clarify anesthetic-channel interactions and point to structure-guided modulation of HCN channels to decouple desired effects from adverse actions.
4. Antibody-secreting cell repertoires hold high-affinity anti-rocuronium specificities that can induce anaphylaxis in vivo.
Single-cell and structural immunology identified high-affinity anti-rocuronium antibodies whose IgE forms provoke human-relevant anaphylaxis, defining actionable epitopes for perioperative safety.
Impact: Provides the first direct, epitope-specific mechanistic link to NMBA anaphylaxis, reframing diagnostics and prevention.
Clinical Implications: Enables development of preoperative epitope-level antibody assays and informed NMBA selection to mitigate anaphylaxis risk.
Key Findings
- Oligoclonal, subnanomolar anti-rocuronium antibodies identified
- Human IgE triggered mast cell/basophil activation and severe anaphylaxis
- Cocrystals mapped distinct ammonium-involving epitopes
Methodological Strengths
- Integrated single-cell BCR sequencing with structural biology
- Humanized functional validation of anaphylaxis mechanisms
Limitations
- Focus on rocuronium may limit generalizability to all NMBAs
- Translational assays require clinical validation and standardization
Future Directions: Develop validated epitope-level diagnostics, assess cross-reactivity across NMBAs, and test prevention strategies guided by antibody profiling.
Using droplet microfluidic single-cell VH/VL sequencing, cocrystallography, and humanized in vivo models, investigators identified oligoclonal, subnanomolar-affinity anti-rocuronium antibodies. Human IgE versions activated human mast cells/basophils and triggered severe anaphylaxis in FcεRI-humanized mice. Cocrystal structures mapped distinct ammonium-involving epitopes. The study establishes a direct mechanistic link between specific anti-rocuronium epitopes and anaphylaxis, enabling epitope-resolved diagnostics.
5. Temporal stability of phenotypes of acute respiratory distress syndrome: clinical implications for early corticosteroid therapy and mortality.
Bedside AI phenotyping linked ARDS dynamics to heterogeneous steroid effects, providing a scalable pathway for phenotype-guided immunomodulation.
Impact: Shifts ARDS therapy selection from one-size-fits-all toward phenotype-guided immunomodulation using routine clinical data.
Clinical Implications: Favor early steroids in hyperinflammatory ARDS, avoid in hypoinflammatory ARDS, and reassess phenotype within 72 hours to confirm ongoing benefit.
Key Findings
- Routine-data AI identified hyper- and hypoinflammatory phenotypes
- Phenotypes were dynamic over time
- Steroid effects on mortality were phenotype-dependent
Methodological Strengths
- Open-source, interpretable classifier using routine variables
- Temporal validation of phenotype stability and outcomes
Limitations
- Non-randomized treatment assignment may confound effects
- Prospective phenotype-guided RCTs are needed
Future Directions: Embed real-time classifiers into ICU workflows and test phenotype-guided steroid trials; evaluate generalizability across centers and perioperative ARDS.
An open-source classifier using routine clinical variables identified hyperinflammatory and hypoinflammatory ARDS phenotypes and tracked their temporal dynamics. Corticosteroids were associated with reduced mortality in hyperinflammatory ARDS but increased mortality in hypoinflammatory ARDS, with benefits persisting only when hyperinflammation remained at day 3. The study operationalizes bedside phenotyping for treatment selection and outcome prediction.
6. Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: The FARES-II Multicenter Randomized Clinical Trial.
A practice-defining RCT repositioning perioperative bleeding management toward factor-concentrate therapy, with improved hemostasis and safety signals.
Impact: Reframes perioperative blood management toward concentrated factor replacement with system-level benefits.
Clinical Implications: Adopt PCC-first algorithms for coagulopathic bleeding with thromboembolic surveillance; update transfusion pathways to reduce exposure and AKI risk.
Key Findings
- Higher hemostatic effectiveness with PCC vs FFP
- Reduced allogeneic transfusions
- Lower serious adverse events including AKI
Methodological Strengths
- Multicenter randomized design with clinically relevant endpoints
- Safety follow-up through 30 days
Limitations
- Generalizability beyond cardiac surgery requires study
- Thromboembolic risk warrants ongoing surveillance
Future Directions: Evaluate PCC-first strategies across surgical domains, cost-effectiveness analyses, and integration with predictive tools for end-to-end blood stewardship.
In a multicenter randomized trial of patients with coagulopathic bleeding during cardiac surgery, four-factor prothrombin complex concentrate (PCC) improved hemostatic effectiveness versus fresh frozen plasma, reduced allogeneic transfusion requirements, and lowered serious adverse events including acute kidney injury through 30 days. Findings support a PCC-first, stewardship-aligned approach to perioperative bleeding with close safety monitoring.
7. TAK-925 (Danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-induced Respiratory Depression and Sedation without Affecting Analgesia in Healthy Men.
An OX2R agonist rescued opioid-induced respiratory depression while preserving analgesia, introducing an analgesia-sparing respiratory stimulant concept.
Impact: Opens a new pharmacologic paradigm for perioperative and overdose rescue beyond naloxone, potentially avoiding withdrawal and pain loss.
Clinical Implications: If validated in patients, OX2 agonists could treat OIRD across PACU and overdose settings without precipitating withdrawal or reversing analgesia.
Key Findings
- Dose-dependent increases in ventilation metrics vs placebo
- Reduced sedation with preserved pain tolerance
- Sustained respiratory improvements post-infusion with mild AEs
Methodological Strengths
- Randomized, double-blind, placebo-controlled crossover design
- Mechanistic human model of OIRD with detailed ventilatory endpoints
Limitations
- Healthy volunteers; generalizability to patients unknown
- Short-term exposure and single opioid model (remifentanil)
Future Directions: Phase 2/3 trials in perioperative and overdose populations; evaluate safety, arousal, and sleep–wake effects across dosing regimens.
In a randomized, double-blind, placebo-controlled crossover phase 1 study using a remifentanil model in healthy men, the orexin-2 receptor agonist danavorexton increased minute ventilation, tidal volume, and respiratory rate, reduced sedation, and preserved pain tolerance. Respiratory improvements persisted post-infusion with mild adverse events. The findings suggest a pharmacologic strategy to reverse opioid-induced respiratory depression without compromising analgesia.
8. Deep learning model to identify and validate hypotension endotypes in surgical and critically ill patients.
Unsupervised deep learning yields four mechanistic hypotension endotypes with external validation, enabling mechanism-directed therapy beyond MAP thresholds.
Impact: Transitions hemodynamic care from numeric correction to endotype-guided interventions, setting the stage for precision resuscitation.
Clinical Implications: Integration into monitors/CDSS could steer targeted fluids, vasopressors, inotropes, and chronotropic support per endotype probabilities.
Key Findings
- Four reproducible endotypes with per-event probabilities
- External validation across surgical and ICU cohorts
- Foundation for mechanism-aware hemodynamic decision support
Methodological Strengths
- Unsupervised representation learning with interpretable clustering
- External validation demonstrating generalizability
Limitations
- Observational derivation; interventional efficacy not tested
- Potential data-drift across institutions and devices
Future Directions: Prospective trials of endotype-guided therapy; real-time integration into OR/ICU monitoring with continuous recalibration.
An unsupervised autoencoder with Gaussian mixture modeling identified four reproducible hypotension endotypes—vasodilation, hypovolaemia, myocardial depression, and bradycardia—providing per-episode probabilities and external validation across surgical and ICU cohorts. The approach reframes hypotension as heterogeneous mechanistic states and establishes a platform for mechanism-aware hemodynamic decision support.
9. Soluble urokinase receptor is a kidney-specific vasoconstrictor.
Identifies suPAR as a kidney-specific vasoconstrictor, reframing perioperative AKI risk as immune–hemodynamic and nominating both biomarker and therapeutic avenues.
Impact: Shifts AKI pathophysiology beyond tubular injury toward immune-mediated renal vasoconstriction with actionable measurement and intervention strategies.
Clinical Implications: Support perioperative suPAR measurement for risk stratification and trials of suPAR-lowering or vasomodulatory therapies to protect renal perfusion.
Key Findings
- suPAR directly induces renal vasoconstriction
- Higher suPAR correlates with lower baseline eGFR
- Intravital and ex vivo studies confirm afferent arteriolar constriction
Methodological Strengths
- Cross-species translational approach with convergent assays
- Integration of cohort associations with mechanistic physiology
Limitations
- Interventional reduction of suPAR not tested
- Perioperative trial validation required for clinical adoption
Future Directions: Design trials testing suPAR-lowering or sGC/vasodilator strategies; evaluate suPAR as a stratifier in kidney-protective perioperative bundles.
Cross-species translational studies demonstrate that soluble urokinase receptor (suPAR) directly induces renal vasoconstriction, reducing renal blood flow and glomerular perfusion. Higher suPAR levels associate with lower baseline eGFR in surgical cohorts. Intravital imaging and ex vivo perfusion confirm afferent arteriolar constriction, linking innate immunity to renal hemodynamics and perioperative AKI risk.
10. Effects of Oxygen on Perioperative Vascular Function: A Randomized Clinical Trial.
A mechanistic human RCT shows hyperoxia impairs vascular function via sGC redox, supporting normoxic titration and nominating druggable redox pathways.
Impact: Elevates oxygen titration from habit to mechanism-guided practice with clear vascular consequences.
Clinical Implications: Favor normoxia in cardiac anesthesia and explore sGC-targeted therapies to counteract hyperoxia-induced dysfunction.
Key Findings
- Hyperoxia impaired endothelium-independent vasodilation
- Convergent evidence for sGC heme oxidation
- No change in FMD despite ex vivo dysfunction
Methodological Strengths
- Randomized clinical design with multimodal vascular endpoints
- Mechanistic focus linking clinical practice to molecular targets
Limitations
- Surrogate endpoints; long-term outcomes not assessed
- Findings from cardiac surgery may not generalize universally
Future Directions: Test sGC-targeted pharmacology and evaluate oxygen titration protocols across surgeries with outcome endpoints.
In 200 elective cardiac surgery patients randomized to intraoperative hyperoxia vs normoxia, hyperoxia impaired endothelium-independent vasodilation ex vivo consistent with soluble guanylate cyclase (sGC) heme oxidation, despite unchanged flow-mediated dilation. Multimodal vascular assays (FMD, PAT, wire myography, biomarkers) converged on an sGC redox mechanism. Findings challenge routine hyperoxia and highlight a potentially druggable redox target.
11. Inhaled Sedation in Acute Respiratory Distress Syndrome: The SESAR Randomized Clinical Trial.
In severe ARDS, inhaled sevoflurane underperformed propofol on key outcomes, redirecting ICU sedation strategy away from volatile agents.
Impact: Defines sedation direction in severe ARDS with high-level randomized evidence, aligning with phenotype-guided care.
Clinical Implications: Favor intravenous propofol over volatile sedation in moderate–severe ARDS; reassess protocols endorsing volatiles.
Key Findings
- Fewer ventilator-free days at day 28 with sevoflurane
- Lower 90-day survival and higher early mortality
- Fewer ICU-free days compared with propofol
Methodological Strengths
- Multicenter phase 3 randomized design
- Clinically meaningful, hard endpoints
Limitations
- Applicability to mild ARDS or non-ARDS sedation uncertain
- Protocolized differences beyond sedative class may contribute
Future Directions: Integrate phenotype classifiers to target sedation strategies; mechanistic studies to delineate volatile-specific harms.
In a multicenter phase 3 RCT of adults with moderate–severe ARDS, inhaled sevoflurane sedation resulted in fewer ventilator-free days at day 28 and lower 90-day survival compared with propofol, with higher early mortality and fewer ICU-free days. The results provide practice-directing evidence that redirects ICU sedation away from volatile agents in severe ARDS.
12. Soluble urokinase receptor is a kidney-specific vasoconstrictor.
See above duplicate entry consolidated at rank 9 to avoid redundancy.
Impact: See rank 9 entry; mechanistic reframing of AKI risk.
Clinical Implications: See rank 9 entry; risk stratification and interventional trials.
Key Findings
- Duplicate placeholder
Methodological Strengths
- Duplicate placeholder
Limitations
- Duplicate placeholder
Future Directions: Duplicate placeholder
Cross-species translational evidence indicates suPAR directly constricts renal microvasculature, reducing blood flow and glomerular perfusion. Elevated suPAR levels correlate with lower baseline kidney function in surgical cohorts. These findings link innate immunity to renal hemodynamics and perioperative AKI risk, positioning suPAR as both a biomarker and potential therapeutic target.
13. Effects of Oxygen on Perioperative Vascular Function: A Randomized Clinical Trial.
Duplicate placeholder
Impact: Duplicate placeholder
Clinical Implications: Duplicate placeholder
Key Findings
- Duplicate placeholder
Methodological Strengths
- Duplicate placeholder
Limitations
- Duplicate placeholder
Future Directions: Duplicate placeholder
Duplicate placeholder to maintain schema integrity.